| |
|
|
|
|
|
|
|||
|
Blood, 1 March 2004, Vol. 103, No. 5, pp. 1653-1661. Prepublished online as a Blood First Edition Paper on October 30, 2003; DOI 10.1182/blood-2003-04-1148.
Submitted April 14, 2003
Division of Angiology, University of Vienna Medical School, Vienna, Austria * Corresponding author; email: christoph.kopp{at}univie.ac.at.
Activation of inflammatory and procoagulant mechanisms is thought to contribute significantly to the initiation of restenosis, a common complication after balloon angioplasty of obstructed arteries. During this process, expression of tissue factor (TF) represents one of the major physiologic triggers of coagulation that result in thrombus formation and the generation of additional signals leading to vascular smooth muscle cell (VSMC) proliferation and migration. In this study, we have investigated by which mechanisms inhibition of coagulation at an early stage through overexpression of tissue factor pathway inhibitor (TFPI), an endogenous inhibitor of TF, might reduce restenosis. In a rabbit femoral artery model, percutaneous delivery of TFPI using a recombinant adenoviral vector resulted in a significant reduction of the intima to media ratio 21 days after injury. When investigating several markers of inflammation and coagulation, we found reduced neointimal expression of monocyte chemoattractant protein-1, lesional monocyte infiltration, expression of vascular TF and matrix metalloproteinase-2 and -9. Moreover, overexpression of TFPI suppressed the autocrine release of PDGF-BB, MCP-1 and MMP-2 in response to factor VIIa and Xa from VSMC in vitro and inhibited monocyte TF-activity. These results suggest that TFPI exerts its action in vivo not only thorough thrombotic, but also non-thrombotic mechanisms.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||